



Infrastructure on Production and Characterization of  
Nanomaterials, Biomaterials, and Systems in Biomedicine

## **2ª Convocatoria de "Acceso competitivo" a NANBIOSIS de 2023**

### **Acuerdo de Priorización de Solicitudes de Acceso a NANBIOSIS**

#### **por del Comité de Coordinación**

NANBIOSIS ofrece acceso a sus servicios a todos los usuarios, nacionales e internacionales, que pueden provenir del sector público o privado, bajo las modalidades de "Acceso Abierto Competitivo" o "Acceso por Demanda". Las solicitudes de acceso seleccionadas en el modo abierto y competitivo obtendrán prioridad en el acceso a la instalación frente a las solicitudes consideradas en "acceso por demanda". Existen dos convocatorias anuales de acceso competitivo.

El proceso de evaluación de dichas solicitudes se lleva a cabo en tres fases:

- Fase interna: Revisión administrativa interna y consulta con las unidades sobre la viabilidad técnica de los accesos solicitados
- Fase externa: Evaluación por el Comité de Acceso
- Priorización de solicitudes en régimen de acceso competitivo por el Comité de Coordinación de NANBIOSIS

En el marco de la 2ª Convocatoria de Acceso Abierto y Competitivo a la ICTS NANBIOSIS en 2023, el Comité de Coordinación de NANBIOSIS, siguiendo la evaluación de solicitudes y la propuesta de priorización emitida por del Comité de Acceso, acuerda:

- Conceder acceso priorizado en "modo abierto y competitivo" a las solicitudes cuyo código de entrada se destaca con fondo verde en la tabla que se muestra a continuación.
- Establecer un orden de prioridad de acceso de dichas solicitudes en modo competitivo, a cada una de las unidades de NANBIOSIS. (Ordenadas de mayor a menor prioridad en la siguiente tabla).
- Considerar como "accesos a demanda" los indicados en las solicitudes cuyo código de entrada tiene fondo blanco en la siguiente tabla. Los accesos derivados de las solicitudes a demanda solo se realizarán una vez cubiertos los "accesos competitivos".

## **Priorización de Solicitudes de Acceso a NANBIOSIS**

Application	Unit	U1: Services
3277	1	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3284	1	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3310	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING, U1-S4: Consultancy in protein production (On-site&Remote), U1-S5: Training courses in protein production (On-site&Remote)
3311	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING, U1-S4: Consultancy in protein production (On-site&Remote), U1-S5: Training courses in protein production (On-site&Remote)
3313	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3316	1	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING
3317	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3322	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3327	1	U1-S1. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3332	1	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3387	1	U1-S1. Molecular cloning (On-site&Remote) OUTSTANDING
3398	1	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING
3323	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3348	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3312	1	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3314	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3315	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3318	1	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3324	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3392	1	U1-S1. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On-site&Remote) OUTSTANDING, U1-S4: Consultancy in protein production (On-site&Remote), U1-S5: Training courses in protein production (On-site&Remote)
3395	1	U1-S4: Consultancy in protein production (On-site&Remote)
3397	1	U1-S4: Consultancy in protein production (On-site&Remote)
3399	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3325	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3326	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3333	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING

3393	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3394	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
3396	1	U1-S3: Protein purification (On-site&Remote) OUTSTANDING

Application	Unit	U2: Services
3354	2	U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S7. Antibody purification (Remote) OUTSTANDING
3353	2	U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING

Application	Unit	U3: Services
3259	3	U3-S1. Synthesis of peptides and characterization (On-site&Remote) OUTSTANDING

Application	Unit	U6: Services
3383	(With16) 6	U6-S1. Use of High-pressure laboratory-scale plant with 50, 100, and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3335	6	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3336	6	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3328	6	U6-S1. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S2. High-pressure phase analysis – solubility, emulsification OUTSTANDING, U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3329	6	U6-S1. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S2. High-pressure phase analysis – solubility, emulsification OUTSTANDING, U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3275	6	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3321	6	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING

3276	6	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3279	6	U6-S9. Centrifugation (On-site)
3320	6	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3331	6	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3352	6	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
3405	6	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING

Application	Unit	U7: Services
3261	7	U7-S3. Characterization by SEM (On-site&Remote) OUTSTANDING, U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S8. Fabrication of Chromium masks (Remote) OUTSTANDING, U7-S10. Advising and consulting in micro and nanofabrication (On-site&Remote)
3274	7	U7-S1. Training Courses in the Use of nanotechnology equipment (Onsite), U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S9. Thin layer deposition (Remote) OUTSTANDING
3286	7	U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S10. Advising and consulting in micro and nanofabrication (On-site&Remote)
3339	7	U7-S11. Contact angle (On-site&Remote) OUTSTANDING
3260	7	U7-S11. Contact angle (On-site&Remote) OUTSTANDING
3350	7	U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING
3287	7	U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S10. Advising and consulting in micro and nanofabrication (On-site&Remote)
3377	7	U7-S11. Contact angle (On-site&Remote) OUTSTANDING
3378	7	U7-S11. Contact angle (On-site&Remote) OUTSTANDING
3379	7	U7-S11. Contact angle (On-site&Remote) OUTSTANDING
3385	7	U7-S1. Training Courses in the Use of nanotechnology equipment (Onsite), U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S8. Fabrication of Chromium masks (Remote) OUTSTANDING, U7-S9. Thin layer deposition (Remote) OUTSTANDING, U7-S10. Advising and consulting in micro and nanofabrication (On-site&Remote)

Application	Unit	U8: Services
3298	8	U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING
3384	8	U8-S01. Design, fabrication, and encapsulation of microelectrodes (based on gold or platinum) on different rigid (Si, SiC or Pyrex) or flexible polymeric substrates (On-site&Remote) OUTSTANDING, U8-S06 Encapsulation or fabrication of 3D structures via 3D printing
3299	8	U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING

Application	Unit	U9: Services
3338	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3343	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3344	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3345	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3346	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3347	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3355	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3356	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3357	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3358	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING

3359	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3360	9	U9-S01. Synthesis of NPs by laser induced-pyrolysis (Remote) OUTSTANDING, U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3361	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3362	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3364	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3365	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3366	9	U9-S01. Synthesis of NPs by laser induced-pyrolysis (Remote) OUTSTANDING, U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3367	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3368	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3369	9	U9-S01. Synthesis of NPs by laser induced-pyrolysis (Remote) OUTSTANDING, U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3372	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3373	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3374	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING
3341	9	U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING

3342 9 U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING

3363 9 U9-S02. Synthesis of Nps by wet methods and microfluidic technology (Remote) OUTSTANDING, U9-S03. Characterization of nanoparticles (Remote) OUTSTANDING

Application	Unit	U12: Services
3375	12	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S03. Determination of the phase behaviour of surfactant and polymers systems (Remote) OUTSTANDING, U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING, U12-S05. Surface and interfacial tensiometry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
3376	12	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING

Application	Unit	U14: Services
3278	14 (With, 19, 21, 22, 24)	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING
3297	14, (With, 21, 22, 24)	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING

Application	Unit	U16: Services
3383	16 (&6)	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling
3294	16	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling
3301	16	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling
3302	16	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling

3303	16	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling
3304	16	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling
3305	16	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling
3306	16	U16-S04. Characterization by Tof-SIM (Remote) OUTSTANDING
3307	16	U16-S04. Characterization by Tof-SIM (Remote) OUTSTANDING

Application	Unit	U17: Services
3288	17	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
3296	17	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
3319	17	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
3308	17	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING

Application	Unit	U18: Services
3289	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3290	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3291	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3292	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3293	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3264	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING



3265	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3266	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3267	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3268	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3269	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3272	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3273	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3270	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
3271	18	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING

Application	Unit	U19: Services
3278	19 (With 14, 21, 22, 24)	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING
3389	19 (With 21, 22)	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING
3390	19 (With 21, 22)	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING
3391	19 (With 21, 22)	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING
3280	19 (With 21, 22, 24)	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING

Application	Unit	U20: Services
3334	20	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S02. Animal models in oncology (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (Onsite&Remote) OUTSTANDING, U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING, U20-S07. In vivo PK/PD assays (Remote) OUTSTANDING
3382	20	U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING
3281	20	U20-S02. Animal models in oncology (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficay Assays of drugs, nanomedicines, biomaterials, and others (Remote) OUTSTANDING
3300	20	U20-S11. Histological processing, section, and staining (Remote) OUTSTANDING

Application	Unit	U21: Services
3278	21, (With 14, 19, 22, 24)	U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
3297	21, (With 14, 22, 24)	U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
3389	21, (With 19, 22)	U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
3390	21, (With 19, 22)	U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
3391	21, (With 19, 22)	U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
3280	21, (With 19, 22, 24)	U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
3370	21, (With 22)	U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
3371	21, (With 22)	U21-S01. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING

Application	Unit	U22: Services
3278	22 (With 14, 19, 21, 24)	U22-S01. Animal Housing (Remote) OUTSTANDING
3297	22 (With 14, 21, 24)	U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07.
3389	22 (With 19, 21)	Development of animal models of disease in large animals (On-site) OUTSTANDING U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07.
3390	22 (With 19, 21)	Development of animal models of disease in large animals (On-site) OUTSTANDING U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07.
3391	22 (With 19, 21)	Development of animal models of disease in large animals (On-site) OUTSTANDING U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING
3280	22 (With 19, 21, 24)	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site)
3370	22 (With 21)	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site)
3371	22 (With 21)	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site)

Application	Unit	U24: Services
3278	24 (With 14, 19, 21, 22)	U24-S01. Evaluation of therapies for cardiovascular disease
3297	24 (With 14, 21, 22)	U24-S01. Evaluation of therapies for cardiovascular disease
3280	24 (With 19, 21, 22)	U24-S02. Medical Imaging for Minimun Invasive Surgery

Application	Unit	U25: Services
3380	25	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
3349	25	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
3351	25	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING

Application	Unit	U26: Services
3309	26	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
3337	26	U26-S06. Biomedical and metabolomic imaging (On-site)
3400	26	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
3402	26	U26-S02. NMR experiments in solid state (Remote) OUTSTANDING
3403	26	U26-S02. NMR experiments in solid state (Remote) OUTSTANDING
3340	26	U26-S06. Biomedical and metabolomic imaging (On-site)
3401	26	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
3404	26	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING

Application	Unit	U28: Services
3330	28	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (Onsite&Remote)
3282	28	U28-S05. High-Resolution Magic Angle Spinning (HR-MAS) NMR (Onsite&Remote)
3283	28	U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING
3262	28	U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote)
3295	28	U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S012. Cryo-ultramicrotomy (Onsite&Remote) OUTSTANDING, U28-S020. High Content Screening (Onsite&Remote) OUTSTANDING

Application	Unit	U30: Services
3388	30	U30-S01. Sample preparation for proteomic analysis, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S09. Data analysis of proteomics experiments
3386	30	U30-S03. Protein identification by mass spectrometry (MS) or MS/MS

14 de junio de 2023  
Comité de Coordinación de NANBIOSIS